Clinical Trial Update: Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation Phase 1/2 trial evaluating short-term disulfiram administration to reverse latent HIV infection; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Disulfiram (Disulfiram)

Snippet

Sponsor: University of California, San Francisco | Conditions: HIV, Human Immunodeficiency Virus | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-05-05